Westpac Banking Corp Makes New Investment in 10x Genomics $TXG

Westpac Banking Corp acquired a new position in shares of 10x Genomics (NASDAQ:TXG – Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 40,185 shares of the company’s stock, valued at approximately $3,631,000.

Other hedge funds have also bought and sold shares of the company. Carolina Wealth Advisors LLC bought a new position in 10x Genomics during the third quarter valued at $46,000. V Square Quantitative Management LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth about $68,000. Farther Finance Advisors LLC lifted its holdings in shares of 10x Genomics by 29.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 934 shares of the company’s stock worth $84,000 after acquiring an additional 215 shares during the last quarter. Elevation Wealth Partners LLC boosted its stake in shares of 10x Genomics by 332.3% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after purchasing an additional 1,143 shares during the period. Finally, CoreCap Advisors LLC boosted its stake in shares of 10x Genomics by 3,269.2% during the 3rd quarter. CoreCap Advisors LLC now owns 1,752 shares of the company’s stock worth $158,000 after purchasing an additional 1,700 shares during the period. Institutional investors own 84.68% of the company’s stock.

Insider Activity

In related news, CFO Adam Taich sold 46,388 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This represents a 12.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 13,818 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $63.02, for a total value of $870,810.36. Following the transaction, the insider owned 488,182 shares in the company, valued at $30,765,229.64. The trade was a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 190,333 shares of company stock valued at $12,604,970. Insiders own 8.84% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on TXG shares. JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $70.00 to $65.00 and set a “neutral” rating on the stock in a report on Monday, November 9th. Citigroup raised their price objective on shares of 10x Genomics from $50.00 to $60.00 and gave the stock a “hold” rating in a research note on Friday, November 6th. Piper Sandler raised their price objective on shares of 10x Genomics from $47.00 to $80.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Royal Bank Of Canada started coverage on 10x Genomics in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 target price for the company. Finally, Stifel Nicolaus increased their price target on 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $68.40.

View Our Latest Report on 10x Genomics

10x Genomics Price Performance

Shares of TXG opened at $57.38 on Friday. 10x Genomics has a 1-year low of $15.18 and a 1-year high of $102.81. The company has a 50-day moving average of $73.20 and a 200 day moving average of $43.29. The firm has a market capitalization of $7.55 billion, a price-to-earnings ratio of -110.35 and a beta of 2.03.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. The business had revenue of $150.67 million for the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The company’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) EPS. On average, equities analysts anticipate that 10x Genomics will post -0.67 earnings per share for the current fiscal year.

10x Genomics Profile

(Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Read More

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.